Compare CVS Health Corp (CVS) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Morgan Stanley — how do they compare? CVS Health Corp trades at $105.15 (market cap $135.48B), while Morgan Stanley trades at $229 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 2.7× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | MS | |
|---|---|---|
Market Cap | $135.48B | $359.10B |
Sector | Health | Financials |
52-Week High | $106.18 | $228.17 |
52-Week Low | $58.75 | $139.09 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Morgan Stanley (MS) trades at $228.17, up 2.65% on the day, with strong bullish momentum from three consecutive quarterly earnings beats. The stock shows robust revenue growth, reaching $66.0B in 2025, and a net income margin of 25.56%. Technical indicators signal a bullish trend, with moving averages supporting upward movement, while RSI levels suggest mixed short-term momentum. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus favoring Buy ratings (53.85%) and a price target of $225.80, slightly below current levels. Key opportunities include continued earnings outperformance and strategic initiatives in AI and IPO leadership. Risks involve volatile cash flows, high debt levels, and macroeconomic sensitivity. Investors should weigh strong fundamentals against execution risks in a dynamic financial landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
